GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (NYSE:LLY) » Definitions » Beneish M-Score

Eli Lilly and Co (Eli Lilly and Co) Beneish M-Score : -1.88 (As of Apr. 26, 2024)


View and export this data going back to 1970. Start your Free Trial

What is Eli Lilly and Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -1.88 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Eli Lilly and Co's Beneish M-Score or its related term are showing as below:

LLY' s Beneish M-Score Range Over the Past 10 Years
Min: -2.87   Med: -2.39   Max: -1.88
Current: -1.88

During the past 13 years, the highest Beneish M-Score of Eli Lilly and Co was -1.88. The lowest was -2.87. And the median was -2.39.


Eli Lilly and Co Beneish M-Score Historical Data

The historical data trend for Eli Lilly and Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Beneish M-Score Chart

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.03 -2.31 -2.33 -2.40 -1.88

Eli Lilly and Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.40 -2.36 -2.23 -2.13 -1.88

Competitive Comparison of Eli Lilly and Co's Beneish M-Score

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Beneish M-Score falls into.



Eli Lilly and Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Eli Lilly and Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1078+0.528 * 0.9688+0.404 * 0.9203+0.892 * 1.1956+0.115 * 1.2339
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9544+4.679 * 0.080494-0.327 * 1.1065
=-1.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $11,336 Mil.
Revenue was 9353.4 + 9498.6 + 8312.1 + 6960 = $34,124 Mil.
Gross Profit was 7565.4 + 7638.5 + 6504.7 + 5333.3 = $27,042 Mil.
Total Current Assets was $25,727 Mil.
Total Assets was $64,006 Mil.
Property, Plant and Equipment(Net PPE) was $12,914 Mil.
Depreciation, Depletion and Amortization(DDA) was $1,527 Mil.
Selling, General, & Admin. Expense(SGA) was $6,710 Mil.
Total Current Liabilities was $27,293 Mil.
Long-Term Debt & Capital Lease Obligation was $18,321 Mil.
Net Income was 2189.7 + -57.4 + 1763.2 + 1344.9 = $5,240 Mil.
Non Operating Income was -937.5 + -2922.6 + -175.2 + -116.5 = $-4,152 Mil.
Cash Flow from Operations was -311.9 + 2189.5 + 631.9 + 1730.6 = $4,240 Mil.
Total Receivables was $8,559 Mil.
Revenue was 7301.8 + 6941.6 + 6488 + 7810 = $28,541 Mil.
Gross Profit was 5753.7 + 5362.5 + 5057.5 + 5737.9 = $21,912 Mil.
Total Current Assets was $18,035 Mil.
Total Assets was $49,490 Mil.
Property, Plant and Equipment(Net PPE) was $10,144 Mil.
Depreciation, Depletion and Amortization(DDA) was $1,523 Mil.
Selling, General, & Admin. Expense(SGA) was $5,880 Mil.
Total Current Liabilities was $17,138 Mil.
Long-Term Debt & Capital Lease Obligation was $14,738 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(11336.2 / 34124.1) / (8558.9 / 28541.4)
=0.332205 / 0.299877
=1.1078

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(21911.6 / 28541.4) / (27041.9 / 34124.1)
=0.767713 / 0.792458
=0.9688

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (25727 + 12913.6) / 64006.3) / (1 - (18034.5 + 10144) / 49489.8)
=0.3963 / 0.43062
=0.9203

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=34124.1 / 28541.4
=1.1956

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1522.5 / (1522.5 + 10144)) / (1527.3 / (1527.3 + 12913.6))
=0.130502 / 0.105762
=1.2339

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(6709.8 / 34124.1) / (5879.9 / 28541.4)
=0.196629 / 0.206013
=0.9544

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((18320.8 + 27293.2) / 64006.3) / ((14737.5 + 17138.2) / 49489.8)
=0.712649 / 0.644086
=1.1065

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(5240.4 - -4151.8 - 4240.1) / 64006.3
=0.080494

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Eli Lilly and Co has a M-score of -1.88 suggests that the company is unlikely to be a manipulator.


Eli Lilly and Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co (Eli Lilly and Co) Business Description

Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Executives
Lilly Endowment Inc 10 percent owner 2801 NORTH MERIDIAN ST, INDIANAPOLIS IN 46208
Donald A Zakrowski officer: Chief Accounting Officer LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Alonzo Weems officer: SVP, ERM & CECO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Patrik Jonsson officer: SVP and Pres., Lilly Bio-Meds LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Anne E. White officer: SVP & Pres-Lilly Oncology LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Eric Dozier officer: EVP, HR & Diversity LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Jackson P Tai director
Mary Lynne Hedley director C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Marschall S Runge director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Naarden Jacob Van officer: SVP, CEO LoxoONC, Pres LlyONC C/O ELI LILLY & CO, LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Diogo Rau officer: SVP & CIDO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Edgardo Hernandez officer: SVP & Pres., Mfg. Operations LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Kimberly H Johnson director C/O FANNIE MAE, 1100 15TH STREET, NW, WASHINGTON DC 20005
Anat Ashkenazi officer: SVP & CFO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Gabrielle Sulzberger director 450 LEXINGTON AVENUE, FLOOR 13, NEW YORK NY 10017